Chandigarh: Union Health and Family Welfare Minister J P Nadda handed over a citation and an award of Rs 1.5 crore to PGIMER, Chandigarh during a function held in New Delhi on Thursday for bestowing Kayakalp awards to different institutes.
PGIMER Chandigarh has been ranked second in category A of central government institutions.
Along with PGIMER Director Jagat Ram, Deputy Director Amitabh Avasthi and Medical Superintendent A K Gupta received the award.
The award's criteria and weightage were based on internal, external and peer assessment of hospital upkeep, sanitation and hygiene, support services, waste management, infection control, hygiene promotion and feedback mechanism from public on cleanliness.
There were two categories of hospital assessed based on infrastructure, patient load, bed strength, support structure among others. PGIMER, Chandigarh was under category A. Other hospitals were AIIMS, New Delhi, Dr RML Hospital, New Delhi, Safdarjung Hospital, New Delhi, LHMC and Associate Hospitals, New Delhi, JIPMER, Puducherry, RIMS, Imphal, Manipur and Mahatma Gandhi Institute of Medical Sciences, Wardha.
PGIMER Chandigarh stood third in 2016-17 and was awarded the first prize in 2015-16.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!